Skip to content
  • Clinical Studies
  • Pharma GMP
  • Pharma Tips
  • Stability Studies
  • Pharma Books
  • Schedule M

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • SOP – Blog Post
  • Toggle search form

BA-BE Studies: SOP for Documenting Protocol Violations and CAPA – V 2.0

Posted on By

BA-BE Studies: SOP for Documenting Protocol Violations and CAPA – V 2.0

Standard Operating Procedure for Documenting Protocol Violations and CAPA in BA/BE Studies

Department BA-BE Studies
SOP No. SOP/BA-BE/115/2025
Supersedes SOP/BA-BE/115/2022
Page No. Page 1 of 10
Issue Date 17/04/2025
Effective Date 20/04/2025
Review Date 17/04/2026

1. Purpose

To establish a uniform process for identifying, documenting, evaluating, and resolving protocol violations that occur during the conduct of Bioavailability/Bioequivalence (BA/BE) studies, including implementation of Corrective and Preventive Actions (CAPA).

2. Scope

This SOP applies to all clinical, QA, data management, and regulatory staff involved in the conduct, monitoring, and oversight of BA/BE trials at the study site or sponsor

level.

3. Responsibilities

  • Principal Investigator (PI): Reviews and classifies protocol violations, ensures documentation, and initiates CAPA.
  • QA Manager: Oversees protocol deviation tracking, supports root cause analysis, and verifies CAPA implementation.
  • Study Coordinator: Documents deviations using the deviation report form and informs the PI and QA.
  • Regulatory Affairs: Communicates reportable violations to Ethics Committees and regulatory authorities.
See also  BA-BE Studies: SOP for Handling Expired Reference Products - V 2.0

4. Accountability

The Head of Clinical Research and the QA Head are jointly accountable for ensuring protocol violations are properly classified, documented, addressed, and reported per GCP and regulatory standards.

5. Procedure

5.1 Identification of Protocol Violations

  1. Any deviation from the approved protocol, GCP, or SOPs must be reported immediately by the staff member observing it.
  2. Examples include:
    • Missed timepoints for blood draws
    • Enrollment of ineligible subjects
    • Failure to obtain consent
    • Unapproved dose substitution

5.2 Classification

  1. Classify violations as:
    • Minor: No impact on subject safety or data integrity
    • Major: Potential impact on data integrity but no subject harm
    • Critical: Potential or actual impact on subject safety and/or trial validity
  2. Document the classification in Annexure-1: Protocol Violation Log.

5.3 Documentation

  1. Fill Annexure-2: Protocol Deviation Report Form within 24 hours of detection.
  2. Each report should include:
    • Date and time of event
    • Volunteer ID
    • Description of deviation
    • Immediate corrective action
See also  BA-BE Studies: SOP for Review of Bioequivalence Waiver Justifications (BCS Class I) - V 2.0

5.4 Root Cause Analysis and CAPA

  1. QA and PI shall perform root cause analysis using Annexure-3: CAPA Worksheet.
  2. Document:
    • Root cause
    • Corrective action taken
    • Preventive measures implemented to avoid recurrence

5.5 Review and Approval

  1. PI to review and sign off the deviation and CAPA forms.
  2. QA to verify and close the deviation after implementation of CAPA.

5.6 Reporting to Ethics and Regulatory Authorities

  1. For critical violations:
    • Submit deviation report to Ethics Committee within 7 working days
    • Submit to CDSCO or relevant authority, if required
  2. Maintain Annexure-4: Regulatory Submission Log for tracking communications.

6. Abbreviations

  • BA: Bioavailability
  • BE: Bioequivalence
  • PI: Principal Investigator
  • QA: Quality Assurance
  • CAPA: Corrective and Preventive Action
  • CDSCO: Central Drugs Standard Control Organization

7. Documents

  1. Protocol Violation Log – Annexure-1
  2. Protocol Deviation Report Form – Annexure-2
  3. CAPA Worksheet – Annexure-3
  4. Regulatory Submission Log – Annexure-4

8. References

  • ICH E6(R2) – Good Clinical Practice
  • Schedule Y – Drugs and Cosmetics Rules
  • CDSCO Guidelines for Protocol Deviations
See also  BA-BE Studies: SOP for Contingency Plan for Power or Equipment Failure - V 2.0

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Protocol Violation Log

Date Volunteer ID Violation Type Classification Status
15/04/2025 VOL-115-003 Missed 1hr sample Major Closed

Annexure-2: Protocol Deviation Report Form

Date Study Code Volunteer ID Description Immediate Action
15/04/2025 BE-115 VOL-115-003 Sample not collected at 1hr Notified PI, noted in CRF

Annexure-3: CAPA Worksheet

Root Cause Corrective Action Preventive Action Verified By
Scheduling oversight Staff informed immediately Updated sampling checklist QA Officer

Annexure-4: Regulatory Submission Log

Date Submitted To Violation Summary Response Received
16/04/2025 IEC Major deviation: sample missed Accepted with note

Revision History:

Revision Date Revision No. Details Reason Approved By
10/01/2022 1.0 Initial release Regulatory Requirement QA Head
17/04/2025 2.0 CAPA process and deviation classification added Audit Recommendation QA Head
BA-BE Studies V 2.0 Tags:Absolute bioavailability, AUC (area under the curve), Bioavailability, Bioequivalence, Bioequivalence criteria, CDSCO bioequivalence norms, Clinical trial registration, Cmax (maximum concentration), Confidence interval %, Crossover study design, EMA bioequivalence requirements, Ethics committee approval, FDA bioequivalence guidelines, Generic drug approval, Good Clinical Practice (GCP), Good Laboratory Practice (GLP), Half-life (t½), ICH E(R) compliance, In vitro dissolution, In vivo studies, Informed consent process, Pharmacodynamics, Pharmacokinetics, Randomized controlled trial, Regulatory submission process, Relative bioavailability, Sample size calculation, Therapeutic equivalence, Tmax (time to maximum concentration), Washout period

Post navigation

Previous Post: Biosimilars: SOP for Documentation of Clone Selection and Results – V 2.0
Next Post: API Manufacturing: SOP for Visual Inspection of Semi-Solid Intermediates – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version